Median OS was 35.0 months in the enzalutamide-alone arm vs 42.3 months in the combination arm. The combination of enzalutamide (Xtandi) plus radium-223 (Ra223, Xofigo) for the treatment of metastatic ...

On Cox regression analysis, glycoproteins were predictive of PFS response to nivolumab plus cabozantinib vs sunitinib (P < .01). Serum glycoproteins involved in complement cascade and lipid metabolism ...

New findings from the open-label SPLASH trial show patients with mCRPC achieved improved progression-free survival as well as response rates and antigen-specific reductions. Prostate-specific membrane ...

“NKT2152 demonstrated robust anti-tumor activity in a heavily pretreated, high-risk advanced clear cell renal cell carcinoma population," said Eric Jonasch, MD. The investigational oral HIF-2α ...

“I think that these data in this approximately 700 patient trial consolidates and makes a strong case for the role of pembrolizumab in the adjuvant setting,” says Guru P. Sonpavde, MD. In this video, ...

“Today, we're presenting the results of this analysis, and we show that patients who have a high Decipher score derive significant benefit from docetaxel,” says Gerhardt Attard, MD, PhD, FRCP. In this ...

Investigators observed promising clinical effect with the EGFR / HER3 bispecific antibody-drug conjugate. Epidermal growth factor receptor (EGFR) / epidermal growth factor 3 (HER3) bispecific antibody ...

The results “support the prioritized development of TAR-200 monotherapy in patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer," said Michiel van der Heijden, MD, PhD. Results ...

According to the authors, “darolutamide significantly reduced the risk of radiological progression or death by 46%” (HR=0.54, 95% CI, 0.41-0.71, P < .0001). Results of the phase 3 ARANOTE study ...

“The overall survival showed a 25% reduction in the risk of death. This is statistically significant,” said Thomas B. Powles, MBBS, MRCP, MD. Results of a large phase 3 study support the use of ...

Radium223 (Xofigo), a calcium mimetic radioactive therapy indicated to treat prostate cancer, may be a particularly beneficial symptom-treating therapy as a regimen prior to chemotherapy in patients ...

At a median follow-up of 44.8 months, median DFS in the pembrolizumab arm was 29.6 months vs 14.2 months in the observation arm. After a median 45 months of follow-up, data indicate that adjuvant ...